News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental HIV treatments
The 2018 Pipeline Report

Welcome to the 2018 Pipeline Report, Treatment Action Group’s annual review of therapeutics, diagnostics, vaccines, and preventive technologies in development for HIV, hepatitis C virus (HCV), and tuberculosis, along with immune-based and gene therapies and research toward a cure for HIV.

Published
24 July 2018
From
TAG
Pharmaceutical industry
The Hepatitis Drug Market Is Worse Than Wall Street Realises

Slowing hepatitis C drug sales have taken a bite out of Gilead's share price.This is a smart retreat for Merck and J&J. The HCV market is well past its peak. Both of their new therapies would have been very late; AbbVie and Gilead both had new drugs approved this year. Their best hope likely would have been to compete on price in a market that's been warring over price for a while.

Published
04 October 2017
From
Bloomberg
New and experimental hepatitis C treatment
Is HCV Drug Development Nearing Its End?

The FDA recently approved two new combination regimens for hepatitis C, raising the question of whether further drug development is warranted in this area. Experts agree, however, that more remains to be done in terms of implementation: getting everyone at risk screened for HCV infection, and getting those who test positive on effective treatment.

Published
02 October 2017
From
MedPage Today
Pharmaceutical industry
J&J unit ends hepatitis C drug development in crowded market

Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies.

Published
11 September 2017
From
Reuters
New and experimental hepatitis C treatment
European and US regulators approve AbbVie's new combo for all hepatitis C genotypes

The European Commission and the US Food and Drug Administration (FDA) last week approved AbbVie's new combination pill for people with hepatitis C virus (HCV)

Published
07 August 2017
By
Liz Highleyman
New and experimental hepatitis C treatment
European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

AbbVie today announced that the European Commission has granted marketing authorization for MAVIRET® (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). MAVIRET is a new 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment,* who comprise the majority of the 71 million people living with HCV globally.

Published
31 July 2017
From
AbbVie press release
New and experimental hepatitis C treatment
European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), as a once-daily single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Published
31 July 2017
From
Gilead press release
New and experimental hepatitis C treatment
Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

AbbVie's new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday

Published
26 July 2017
By
Liz Highleyman
New and experimental hepatitis C treatment
WHO prequalifies first generic hepatitis C medicine and first HIV self-test

WHO today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis C. The development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. Sofosbuvir, 400 mg tablet, is manufactured by Mylan Laboratories Ltd., India.

Published
22 July 2017
From
World Health Organization
New and experimental hepatitis C treatment
US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment

On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi

Published
19 July 2017
By
Liz Highleyman
← First12345...65Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.